Tip60-Dependent Acetylation of p53 Modulates the Decision between Cell-Cycle Arrest and Apoptosis

Molecular Cell

Volumn 24, Issue 6, 2006, Pages 827-839

  Tang, Yi ^a   Luo, Jianyuan ^a   Zhang, Wenzhu ^a   Gu, Wei ^a  

^a Columbia University ^*  (United States)

Author keywords

CELLCYCLE

Indexed keywords

ARGININE; DNA; HISTONE ACETYLTRANSFERASE; LYSINE; MUTANT PROTEIN; PROTEIN P53; PROTEIN TIP60; TUMOR SUPPRESSOR PROTEIN;

ACETYLATION; APOPTOSIS; ARTICLE; CANCER CELL; CELL CYCLE ARREST; CELL CYCLE REGULATION; CELL STRESS; CONTROLLED STUDY; DNA BINDING MOTIF; DNA DAMAGE; GENE MUTATION; HUMAN; HUMAN CELL; NONHUMAN; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN MODIFICATION; PROTEIN PROCESSING; REGULATORY MECHANISM;

ACETYLATION; AMINO ACID SEQUENCE; ANIMALS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; BINDING SITES; CATALYSIS; CELL CYCLE; CELL CYCLE PROTEINS; CELL PROLIFERATION; CYCLIN-DEPENDENT KINASE INHIBITOR P21; HISTONE ACETYLTRANSFERASES; HUMANS; MICE; MODELS, BIOLOGICAL; MOLECULAR SEQUENCE DATA; P300-CBP TRANSCRIPTION FACTORS; PROMOTER REGIONS (GENETICS); PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-MDM2; SEQUENCE HOMOLOGY, AMINO ACID; TRANS-ACTIVATION (GENETICS); TRANSCRIPTION FACTORS; TRANSFECTION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 33845668241     PISSN: 10972765     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.molcel.2006.11.021     Document Type: Article

References (68)

1. Appella E., and Anderson C.W. Post-translational modifications and activation of p53 by genotoxic stresses. Eur. J. Biochem. 268 (2001) 2764-2772
2. Avantaggiati M.L., Ogryzko V., Gardner K., Giordano A., Levine A.S., and Kelly K. Recruitment of p300/CBP in p53-dependent signal pathways. Cell 89 (1997) 1175-1184
3. Barlev N.A., Liu L., Chehab N.H., Mansfield K., Harris K.G., Halazonetis T.D., and Berger S.L. Acetylation of p53 activates transcription through recruitment of coactivators/histone acetyltransferases. Mol. Cell 8 (2001) 1243-1254
4. Berns K., Hijmans E.M., Mullenders J., Brummelkamp T.R., Velds A., Heimerikx M., Kerkhoven R.M., Madiredjo M., Nijkamp W., Weigelt B., et al. A large-scale RNAi screen in human cells identifies new components of the p53 pathway. Nature 428 (2004) 431-437
5. Brodsky M.H., Nordstrom W., Tsang G., Kwan E., Rubin G.M., and Abrams J.M. Drosophila p53 binds a damage response element at the reaper locus. Cell 101 (2000) 103-113
6. Brooks C.L., and Gu W. Ubiquitination, phosphorylation and acetylation: the molecular basis for p53 regulation. Curr. Opin. Cell Biol. 15 (2003) 164-171
7. Brooks C.L., and Gu W. p53 ubiquitination: Mdm2 and beyond. Mol. Cell 21 (2006) 307-315
8. Chipuk J.E., Kuwana T., Bouchier-Hayes L., Droin N.M., Newmeyer D.D., Schuler M., and Green D.R. Direct activation of Bax by p53 mediates mitochondrial membrane permeabilization and apoptosis. Science 303 (2004) 1010-1014
9. Cho Y., Gorina S., Jeffrey P.D., and Pavletich N.P. Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. Science 265 (1994) 346-355
10. Chuikov S., Kurash J.K., Wilson J.R., Xiao B., Justin N., Ivanov G.S., McKinney K., Tempst P., Prives C., Gamblin S.J., et al. Regulation of p53 activity through lysine methylation. Nature 432 (2004) 353-360
11. Deissler H., Kafka A., Schuster E., Sauer G., Kreienberg R., and Zeillinger R. Spectrum of p53 mutations in biopsies from breast cancer patients selected for preoperative chemotherapy analysed by the functional yeast assay to predict therapeutic response. Oncol. Rep. 11 (2004) 1281-1286
12. el-Deiry W.S., Tokino T., Velculescu V.E., Levy D.B., Parsons R., Trent J.M., Lin D., Mercer W.E., Kinzler K.W., and Vogelstein B. WAF1, a potential mediator of p53 tumor suppression. Cell 75 (1993) 817-825
13. Feng L., Lin T., Uranishi H., Gu W., and Xu Y. Functional analysis of the roles of posttranslational modifications at the p53 C terminus in regulating p53 stability and activity. Mol. Cell. Biol. 25 (2005) 5389-5395
14. Glozak M.A., Sengupta N., Zhang X., and Seto E. Acetylation and deacetylation of non-histone proteins. Gene 363 (2005) 15-23
15. Gu W., and Roeder R.G. Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain. Cell 90 (1997) 595-606
16. Gu W., Shi X.L., and Roeder R.G. Synergistic activation of transcription by CBP and p53. Nature 387 (1997) 819-823
17. Hainaut P., and Hollstein M. p53 and human cancer: the first ten thousand mutations. Adv. Cancer Res. 77 (2000) 81-137
18. Hashimoto T., Tokuchi Y., Hayashi M., Kobayashi Y., Nishida K., Hayashi S., Ishikawa Y., Tsuchiya S., Nakagawa K., Hayashi J., and Tsuchiya E. p53 null mutations undetected by immunohistochemical staining predict a poor outcome with early-stage non-small cell lung carcinomas. Cancer Res. 59 (1999) 5572-5577
19. Hayes V.M., Dirven C.M., Dam A., Verlind E., Molenaar W.M., Mooij J.J., Hofstra R.M., and Buys C.H. High frequency of TP53 mutations in juvenile pilocytic astrocytomas indicates role of TP53 in the development of these tumors. Brain Pathol. 9 (1999) 463-467
20. Hussain S.P., and Harris C.C. p53 mutation spectrum and load: the generation of hypotheses linking the exposure of endogenous or exogenous carcinogens to human cancer. Mutat. Res. 428 (1999) 23-32
21. Huyen Y., Jeffrey P.D., Derry W.B., Rothman J.H., Pavletich N.P., Stavridi E.S., and Halazonetis T.D. Structural differences in the DNA binding domains of human p53 and its C. elegans ortholog Cep-1. Structure 12 (2004) 1237-1243
22. Ikura T., Ogryzko V.V., Grigoriev M., Groisman R., Wang J., Horikoshi M., Scully R., Qin J., and Nakatani Y. Involvement of the TIP60 histone acetylase complex in DNA repair and apoptosis. Cell 102 (2000) 463-473
23. Ito A., Lai C.H., Zhao X., Saito S., Hamilton M.H., Appella E., and Yao T.P. p300/CBP-mediated p53 acetylation is commonly induced by p53-activating agents and inhibited by MDM2. EMBO J. 20 (2001) 1331-1340
24. Ito A., Kawaguchi Y., Lai C.H., Kovacs J.J., Higashimoto Y., Appella E., and Yao T.P. MDM2-HDAC1-mediated deacetylation of p53 is required for its degradation. EMBO J. 21 (2002) 6236-6245
25. Jeffers J.R., Parganas E., Lee Y., Yang C., Wang J., Brennan J., MacLean K.H., Han J., Chittenden T., Ihle J.N., et al. Puma is an essential mediator of p53-dependent and -independent apoptotic pathways. Cancer Cell 4 (2003) 321-328
26. Kamine J., Elangovan B., Subramanian T., Coleman D., and Chinnadurai G. Identification of a cellular protein that specifically interacts with the essential cysteine region of the HIV-1 Tat transactivator. Virology 216 (1996) 357-366
27. Kern S.E., Pietenpol J.A., Thiagalingam S., Seymour A., Kinzler K.W., and Vogelstein B. Oncogenic forms of p53 inhibit p53-regulated gene expression. Science 256 (1992) 827-830
28. Krummel K.A., Lee C.J., Toledo F., and Wahl G.M. The C-terminal lysines fine-tune P53 stress responses in a mouse model but are not required for stability control or transactivation. Proc. Natl. Acad. Sci. USA 102 (2005) 10188-10193
29. Kusch T., Florens L., Macdonald W.H., Swanson S.K., Glaser R.L., Yates III J.R., Abmayr S.M., Washburn M.P., and Workman J.L. Acetylation by Tip60 is required for selective histone variant exchange at DNA lesions. Science 306 (2004) 2084-2087
30. Lane D.P. Cancer. p53, guardian of the genome. Nature 358 (1992) 15-16
31. Legube G., Linares L.K., Lemercier C., Scheffner M., Khochbin S., and Trouche D. Tip60 is targeted to proteasome-mediated degradation by Mdm2 and accumulates after UV irradiation. EMBO J. 21 (2002) 1704-1712
32. Legube G., Linares L.K., Tyteca S., Caron C., Scheffner M., Chevillard-Briet M., and Trouche D. Role of the histone acetyl transferase Tip60 in the p53 pathway. J. Biol. Chem. 279 (2004) 44825-44833
33. Leitao M.M., Soslow R.A., Baergen R.N., Olvera N., Arroyo C., and Boyd J. Mutation and expression of the TP53 gene in early stage epithelial ovarian carcinoma. Gynecol. Oncol. 93 (2004) 301-306
34. Leu J.I., Dumont P., Hafey M., Murphy M.E., and George D.L. Mitochondrial p53 activates Bak and causes disruption of a Bak-Mcl1 complex. Nat. Cell Biol. 6 (2004) 443-450
35. Levine A.J. p53, the cellular gatekeeper for growth and division. Cell 88 (1997) 323-331
36. Li M., Luo J., Brooks C.L., and Gu W. Acetylation of p53 inhibits its ubiquitination by Mdm2. J. Biol. Chem. 277 (2002) 50607-50611
37. Lill N.L., Grossman S.R., Ginsberg D., DeCaprio J., and Livingston D.M. Binding and modulation of p53 by p300/CBP coactivators. Nature 387 (1997) 823-827
38. Liu L., Scolnick D.M., Trievel R.C., Zhang H.B., Marmorstein R., Halazonetis T.D., and Berger S.L. p53 sites acetylated in vitro by PCAF and p300 are acetylated in vivo in response to DNA damage. Mol. Cell. Biol. 19 (1999) 1202-1209
39. Luo J., Su F., Chen D., Shiloh A., and Gu W. Deacetylation of p53 modulates its effect on cell growth and apoptosis. Nature 408 (2000) 377-381
40. Luo J., Nikolaev A.Y., Imai S., Chen D., Su F., Shiloh A., Guarente L., and Gu W. Negative control of p53 by Sir2alpha promotes cell survival under stress. Cell 107 (2001) 137-148
41. Luo J., Li M., Tang Y., Laszkowska M., Roeder R.G., and Gu W. Acetylation of p53 augments its site-specific DNA binding both in vitro and in vivo. Proc. Natl. Acad. Sci. USA 101 (2004) 2259-2264
42. Manfredi J.J. p53 and apoptosis: it's not just in the nucleus anymore. Mol. Cell 11 (2003) 552-554
43. Meyers F.J., Chi S.G., Fishman J.R., deVere White R.W., and Gumerlock P.H. p53 mutations in benign prostatic hyperplasia. J. Natl. Cancer Inst. 85 (1993) 1856-1858
44. Michael D., and Oren M. The p53 and Mdm2 families in cancer. Curr. Opin. Genet. Dev. 12 (2002) 53-59
45. Mihara M., Erster S., Zaika A., Petrenko O., Chittenden T., Pancoska P., and Moll U.M. p53 has a direct apoptogenic role at the mitochondria. Mol. Cell 11 (2003) 577-590
46. Murr R., Loizou J.I., Yang Y.G., Cuenin C., Li H., Wang Z.Q., and Herceg Z. Histone acetylation by Trrap-Tip60 modulates loading of repair proteins and repair of DNA double-strand breaks. Nat. Cell Biol. 8 (2006) 91-99
47. Nakano K., and Vousden K.H. PUMA, a novel proapoptotic gene, is induced by p53. Mol. Cell 7 (2001) 683-694
48. Ollmann M., Young L.M., Di Como C.J., Karim F., Belvin M., Robertson S., Whittaker K., Demsky M., Fisher W.W., Buchman A., et al. Drosophila p53 is a structural and functional homolog of the tumor suppressor p53. Cell 101 (2000) 91-101
49. Prives C., and Hall P.A. The p53 pathway. J. Pathol. 187 (1999) 112-126
50. Robert F., Hardy S., Nagy Z., Baldeyron C., Murr R., Dery U., Masson J.Y., Papadopoulo D., Herceg Z., and Tora L. The transcriptional histone acetyltransferase cofactor TRRAP associates with the MRN repair complex and plays a role in DNA double-strand break repair. Mol. Cell. Biol. 26 (2006) 402-412
51. Rodriguez M.S., Desterro J.M., Lain S., Midgley C.A., Lane D.P., and Hay R.T. SUMO-1 modification activates the transcriptional response of p53. EMBO J. 18 (1999) 6455-6461
52. Sachchidanand, Resnick-Silverman L., Yan S., Mutjaba S., Liu W.J., Zeng L., Manfredi J.J., and Zhou M.M. Target structure-based discovery of small molecules that block human p53 and CREB binding protein association. Chem. Biol. 13 (2006) 81-90
53. Sakaguchi K., Herrera J.E., Saito S., Miki T., Bustin M., Vassilev A., Anderson C.W., and Appella E. DNA damage activates p53 through a phosphorylation-acetylation cascade. Genes Dev. 12 (1998) 2831-2841
54. Schumacher B., Hofmann K., Boulton S., and Gartner A. The C. elegans homolog of the p53 tumor suppressor is required for DNA damage-induced apoptosis. Curr. Biol. 11 (2001) 1722-1727
55. Seoane J., Le H.V., and Massague J. Myc suppression of the p21 cdk inhibitor influences the outcome of the p53 response to DNA damage. Nature 419 (2002) 729-734
56. Tyteca S., Vandromme M., Legube G., Chevillard-Briet M., and Trouche D. Tip60 and p400 are both required for UV-induced apoptosis but play antagonistic roles in cell cycleprogression. EMBO J. 25 (2006) 1680-1689
57. Villunger A., Michalak E.M., Coultas L., Mullauer F., Bock G., Ausserlechner M.J., Adams J.M., and Strasser A. p53- and drug-induced apoptotic responses mediated by BH3-only proteins puma and noxa. Science 302 (2003) 1036-1038
58. Vogelstein B., Lane D., and Levine A.J. Surfing the p53 network. Nature 408 (2000) 307-310
59. Vousden K.H., and Lu X. Live or let die: the cell's response to p53. Nat. Rev. Cancer 2 (2002) 594-604
60. Wang Y.H., Tsay Y.G., Tan B.C., Lo W.Y., and Lee S.C. Identification and characterization of a novel p300-mediated p53 acetylation site, lysine 305. J. Biol. Chem. 278 (2003) 25568-25576
61. Wiederschain D., Kawai H., Shilatifard A., and Yuan Z.M. Multiple mixed lineage leukemia (MLL) fusion proteins suppress p53-mediated response to DNA damage. J. Biol. Chem. 280 (2005) 24315-24321
62. Wu W.S., Heinrichs S., Xu D., Garrison S.P., Zambetti G.P., Adams J.M., and Look A.T. Slug antagonizes p53-mediated apoptosis of hematopoietic progenitors by repressing puma. Cell 123 (2005) 641-653
63. Xirodimas D.P., Saville M.K., Bourdon J.C., Hay R.T., and Lane D.P. Mdm2-mediated NEDD8 conjugation of p53 inhibits its transcriptional activity. Cell 118 (2004) 83-97
64. Yang X.J. The diverse superfamily of lysine acetyltransferases and their roles in leukemia and other diseases. Nucleic Acids Res. 32 (2004) 959-976
65. Yu J., Wang Z., Kinzler K.W., Vogelstein B., and Zhang L. PUMA mediates the apoptotic response to p53 in colorectal cancer cells. Proc. Natl. Acad. Sci. USA 100 (2003) 1931-1936
66. Yu J., and Zhang L. The transcriptional targets of p53 in apoptosis control. Biochem. Biophys. Res. Commun. 331 (2005) 851-858
67. Yu J., Zhang L., Hwang P.M., Kinzler K.W., and Vogelstein B. PUMA induces the rapid apoptosis of colorectal cancer cells. Mol. Cell 7 (2001) 673-682
68. Zhao Y., Lu S., Wu L., Chai G., Wang H., Chen Y., Sun J., Yu Y., Zhou W., Zheng Q., et al. Acetylation of p53 at lysine 373/382 by the histone deacetylase inhibitor depsipeptide induces expression of p21Waf1/Cip1. Mol. Cell. Biol. 26 (2006) 2782-2790